Analysts Set Alpine Immune Sciences Inc (ALPN) Price Target at $12.80

Share on StockTwits

Shares of Alpine Immune Sciences Inc (NASDAQ:ALPN) have been assigned a consensus recommendation of “Buy” from the seven brokerages that are presently covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and five have assigned a buy recommendation to the company. The average 1 year price target among brokers that have issued a report on the stock in the last year is $12.80.

A number of equities research analysts have recently weighed in on the company. Piper Jaffray Companies assumed coverage on Alpine Immune Sciences in a research report on Thursday, September 27th. They issued an “overweight” rating and a $12.00 price objective on the stock. ValuEngine lowered Alpine Immune Sciences from a “sell” rating to a “strong sell” rating in a research report on Monday, July 2nd. Citigroup initiated coverage on Alpine Immune Sciences in a research report on Thursday, June 28th. They set an “outperform” rating and a $13.00 price target on the stock. Zacks Investment Research upgraded Alpine Immune Sciences from a “sell” rating to a “hold” rating in a research report on Wednesday, June 20th. Finally, Oppenheimer initiated coverage on Alpine Immune Sciences in a research report on Friday, June 29th. They set an “outperform” rating and a $13.00 price target on the stock.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. DRW Securities LLC boosted its position in shares of Alpine Immune Sciences by 138.7% during the second quarter. DRW Securities LLC now owns 24,343 shares of the biotechnology company’s stock valued at $184,000 after purchasing an additional 14,143 shares in the last quarter. Dimensional Fund Advisors LP boosted its position in shares of Alpine Immune Sciences by 122.2% during the second quarter. Dimensional Fund Advisors LP now owns 32,819 shares of the biotechnology company’s stock valued at $248,000 after purchasing an additional 18,052 shares in the last quarter. Finally, Renaissance Technologies LLC boosted its position in shares of Alpine Immune Sciences by 20.9% during the second quarter. Renaissance Technologies LLC now owns 122,424 shares of the biotechnology company’s stock valued at $927,000 after purchasing an additional 21,124 shares in the last quarter. Institutional investors own 56.87% of the company’s stock.

Shares of ALPN stock remained flat at $$5.00 during trading hours on Friday. The stock had a trading volume of 43,193 shares, compared to its average volume of 18,307. The company has a market cap of $87.65 million, a price-to-earnings ratio of -4.17 and a beta of 0.54. Alpine Immune Sciences has a 12-month low of $4.89 and a 12-month high of $12.24. The company has a current ratio of 20.99, a quick ratio of 20.99 and a debt-to-equity ratio of 0.05.

Alpine Immune Sciences (NASDAQ:ALPN) last issued its quarterly earnings data on Thursday, August 9th. The biotechnology company reported ($0.57) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.44) by ($0.13). The business had revenue of $0.39 million during the quarter, compared to the consensus estimate of $0.30 million. Alpine Immune Sciences had a negative return on equity of 26.00% and a negative net margin of 1,602.19%. On average, research analysts forecast that Alpine Immune Sciences will post -2.12 EPS for the current fiscal year.

About Alpine Immune Sciences

Alpine Immune Sciences, Inc focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, inflammatory disorders, and other diseases. Its lead programs include ALPN-101, an ICOS/CD28 antagonist program for the treatment of autoimmune and inflammatory diseases; and ALPN-202 program for the treatment of cancer.

Featured Story: Dividend Aristocrat Index

Analyst Recommendations for Alpine Immune Sciences (NASDAQ:ALPN)

Receive News & Ratings for Alpine Immune Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alpine Immune Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply